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Individual human adenoviruses (Ad)  ~ vary in  their tumorigenic potential  in 
rodents.  Group  A  serotypes  induce tumors  with  high  efficiency, while  those 
belonging to the group C are nononcogenic (1). 
This phenomenon was originally thought to be a  reflection of differences in 
their  immunogenicity (2).  Isograft  transplantation  experiments  have  shown, 
however, that immunization with both highly oncogenic Adl2 (3,  4) and non- 
oncogenic Ad2 and Ad5 (5) serotypes induces a strong transplantation immunity 
against tumorigenic Ad-transformed cells. This immunity has been attributed to 
Ad tumor-specific transplantation antigen (TSTA). 
The identity of Ad TSTA is unknown. The in vitro reactivity of secondary 
cytolytic T  cells against syngeneic Ad-transformed cells is directed against prod- 
uct(s) dependent on expression in the transformed cells of the Ad early region 
E1  (6, 7).  Examination of a series of mutants of Ad5 for their ability to induce 
group CAd TSTA in rats revealed that mutants with defects in the region E1 
produced significantly lower or no TSTA when compared with Ad2 or Ad5 wild 
type viruses (5). 
Adenovirus early gene block E1 contains the region of the viral chromosome 
that has been shown to be responsible for the transforming activity of the virus 
(8). It consists of two transcription units E I A and E 1B (9). Effects of  immunization 
with xenogeneic cells transformed with isolated fi'agments of Ad 12 DNA during 
latency of tumors induced with Ad12 virions suggested that the Ad12 TSTA is 
a  fimction of the left end  of the E1B  early region (10).  This  hypothesis was 
further supported  by evidence that  cells  transformed with a  cloned Acc I-H 
fragment of Adl 2 DNA (0-4.7 map units) failed to elicit secondary cytolytic T 
cells, which were elicited by cells transformed with the Hind III-G fragment (0- 
6.8 map units) of Adl2 DNA (1 1). 
The TSTA immunity is highly specific: immunization with Ad2 (or Ad5) offers 
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FIGURE  1.  Diagrammatic representation of hybrid adenoviruses used for immunization. _, 
the Ad5 chromosome; a,  deletions; and A, insertions. The Ad5 nucleotides present on either 
side of the Ad5-specific E 1 deletions are designated below each chromosome, while the Ad 12 
nucleotides at the extremes  of the  Adl2-specific  El  insertions are designated  above each 
chromosome. The sub304 (14) and in340 (15) have been described previously. 
no  protection  against  Adl2-transformed  cells  (4)  and  vice-versa (5).  This  fact 
offers  an  ideal  opportunity  to  identify  the  adenovirus  genes  responsible  for 
TSTA expression by use of viable recombinant adenoviruses that carry a portion 
of the type 12 E 1 A  and E IB transcription units in a type 5 background. 2 
Results we report in this paper do not support the hypothesis that the major 
component  of  adenovirus  TSTA  is  coded  by  the  E1B  region.  We  provide 
experimental  evidence  that  the  in  vivo TSTA  activity of the  highly oncogenic 
Ad 12 and the nononcogenic Ad5 is a  function of their respective E I A  genes. 
Materials and  Methods 
Animals.  Lister-Hooded (LIS) rats of RT-1 c haplotype, originally obtained from Dr. 
Phillip H. Gallimore of the University of Birmingham, England, were bred by brother- 
sister mating. 
Viruses.  The viable recombinant viruses sub370-12EIA, sub370-12E1B, and sub370- 
12E1AB were described elsewhere. 2 The genomic structures of these three substitution 
mutants are diagrammed in Fig. 1. The recombinant viruses, as well as wild type Ad5 and 
Adl2 (Huie strain), were grown in 293 cells (12). 
Tumor Cell Lines.  Two tumorigenic LIS cell lines were used throughout this study. 
The EcoC3 cells were transformed in vitro with a  recombinant plasmid containing the 
Eco RI-C fragment (0-16.5 map units) of Adl2 DNA. The Ad2/T13 cell line (5) derived 
from the Ad2/HLREF/50A  cell line (13) was kindly provided by Dr. P.  H. Gallimore. 
Both the EcoC3 and the Ad2/T13  cells  are tumorigenic in mature syngeneic LIS rats. 
For tumorigenicity assays the Ad2/T 13 cell line was passaged in animals and then once 
in tissue culture before storage in liquid nitrogen. 
Assays of Transplantation Immunity.  Randomized 8-wk-old LIS rats were immunized 
with two subcutaneous injections (1 wk apart) of ~108 PFU of the individual viruses in a 
volume of 0.3-0.5  ml.  In experiments with Ad5 and Adl2  viruses the control animals 
received an identical volume of PBS.  In experiments with the recombinant adenoviruses, 
an  equivalent volume of uninfected  293  cell extract was injected into control  rats.  In 
some experiments with the recombinant viruses, additional control animals were injected 
with 0.5  ml of PBS.  3 wk after the second injection the animals were challenged with 
various doses of the tumorigenic EcoC 3 cells or Ad2/T 13 cells inoculated subcutaneously. 
The animals were observed for at least 100 d for tumor development, and tumor size was 
measured with a caliper. This 50% tumor-producing dose (TPDs0) was calculated where 
indicated by the  method of Karber (16).  At the  end  of the experiment all apparently 
tumor-free animals were killed, autopsied, and examined for the presence of tumors. 
Statistical methods.  The significance of differences in distribution of tumors between 
control and immunized rat populations was determined by the use of Fisher's exact test 
(17). 
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TABLE  I 
Induction of Transplantation Immunity Against Adenovirus-transformed Cells With Wild Type 
Adenoviruses 5 and 12 
Tumor-positive rats  Tumor-positive rats 
Immuniza-  at Ad12-EcoC3 cell  at Ad2-T13 cell 
tion  doses of:  TPDs0*  doses of:  TPDs0* 
10  7  10  6  l0 s  10  7  l0  s  l0 s 
Control  --  5/5  2/5  1.3 x  105  --  4/4  1/5  2  X  105 
Ad5  5/5  5/5  --  -<3.2 X  l0 s  0/4  0/4  --  ->3.2 X  107 
Adl2  0/5  0/5  --  ->3.2 x  107  4/4  4/4  --  -<3.2 X  105 
Animals were injected subcutaneously with  108 PFU of the two viruses at 8 wk of age and boosted 
1 wk later.  Control animals were injected with  PBS.  3  wk after the second injection, the animals 
were challenged subcutaneously with various doses of the two tumorigenic cell lines. The inoculated 
animals were followed for tumor development for  120 d. 
* The estimated dose producing tumors in 50% of animals, calculated by the method of Karber (16). 
Results 
Transplantation Immunity Induced  by  Wild  Type Adenoviruses  5  and  12.  To 
study the adenovirus genes required for induction of specific TSTA immunity, 
we selected two syngeneic cell lines that are tumorigenic in competent adult rats. 
The EcoC3 cells were transformed with the cloned Eco RI-C fragment of Adl2 
DNA; the Ad2/T13 cells were transformed with Ad2 virions. 
All studies  of adenovirus TSTA  immunity  reported  so far  used virus-trans- 
formed cells. The virus functions expressed in such cells usually have not been 
studied and it has not been demonstrated that effective transplantation immunity 
can be induced against cells transformed with the cloned DNA segment encoding 
the  transforming  region.  For  this  reason  the  tumorigenicity  and  effects  of 
immunization  with wild type Ad5 and Adl2, respectively, were examined first. 
Both cell lines are highly tumorigenic  in  12-wk-old rats,  as can be ascertained 
from the TPDs0 values calculated for the subcutaneous inoculation (Table I). 
Immunization with the two Ad serotypes offers a strong group-specific syngraft 
immunity  which  is  apparent  from  the  changed  TPDs0  values  in  immunized 
animals. The two injections of Ad 12 protect against tumor induction with EcoC3 
cells,  while  Ad5  immunization  protects  against  Ad2/T13  tumors.  Growth  of 
either tumor was not affected by immunization with the heteroiogous virus. This 
result  confirms  earlier  studies  that  immunization  with  group  A  and  group  C 
adenoviruses, respectively, is not crossprotective (4, 5). It also shows that a strong 
syngraft  immunity  can  be  induced  against  EcoC3  cells  transformed  with  the 
cloned fragment of the transforming region of Ad 12 DNA, which do not express 
any  additional  Ad  early  functions.  Strong  transplantation  immunity  against 
Ad2/T 13 cells was also induced with Ad2 immunization  (not shown), in agree- 
ment with an earlier report (5).  This result shows that examination  of the role 
of the E1A and E 1B transcription  units in the protective effects of immunization 
with viable recombinant Ad5/Adl2  adenoviruses on the growth of EcoC3 and 
Ad2/T 13 cells, respectively, is feasible. 
Induction of Syngraft Immunity Against EcoC3 Cells by Immunization With Recom- 
binant Ad5/Adl2  Adenoviruses.  Three  recombinant  viruses were  selected for 
studies of induction  of TSTA immunity: sub 370-12E 1AB, sub 370-12E 1  A, and 566  ADENOVIRUS  TUMOR-SPECIFIC  TRANSPLANTATION  ANTIGEN 
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FIGURE  2.  Growth of 2  X  106 EcoC3  cells in syngeneic LIS rats immunized with different 
recombinant viruses. The LIS rats were immunized with 2 subcutaneous injections of 10  s PFU 
of the recombinant adenoviruses. Control animals received two 0.5-ml injections of the lysate 
extract of uninfected 293 cells. 3  wk after the second injection the rats were challenged with 
2 x  106 EcoC3 cells. The average sizes of the tumors in each individual group of not less than 
three animals are shown. O, control animals; A, sub370-12E1B, O, sub370-12E1A; A, sub370- 
12E1AB. 
sub370-12E1B. 2 As  can  be  seen  in  Fig.  1,  the  entire  E1  region of Ad5  was 
substituted with the Adl2  E1  region in the sub370-12E1AB  virus.  The E1A 
transcription unit only was substituted in the sub 370-12E 1A virus, and the E 1  B 
subregion was substituted in the sub 370-12E1B virus. Immunization with these 
three viruses should establish which of the two subregions of the early region 1 
is required for TSTA activity of Ad 12. 
In the first experiment the 8-wk-old rats were injected with two doses (1  wk 
apart) of the recombinant viruses (10 s PFU). Since the recombinant viruses were 
grown in the Ad5-transformed 293 cells, the control animals were injected twice 
with  uninfected 293  extracts.  3  wk  after the  second  injection  the  rats  were 
challenged with 2 X 106 EcoC3 cells. Results in Fig. 2 show growth of the EcoC3 
tumors in rats immunized with the three viruses. While tumors grew in animals 
immunized with the sub370-12E1B  virus, no tumors developed in rats injected 
with the sub 370-12E 1AB or sub 370-12E 1A viruses. 
The protective effects of the immunization with sub 370-12E 1AB and sub 370- 
12E1A virions were further tested with various doses of the inoculated tumori- 
genic EcoC3 cells  (Fig.  3).  Although the latency period was dependent on the 
inoculated cell dose, tumors in control animals developed with all doses used (2.5 
x  106-2  x  107  cells).  In  rats  immunized with  sub370-12E1AB  and  sub370- 
12E1A  viruses,  respectively,  no  tumors  developed  even  when  animals  were 
challenged with 2 X  10 7 EcoC3 cells (Fig. 3D). 
Results of four additional experiments on the effects of the immunization with 
recombinant Ad5/Adl2 adenoviruses on tumorigenicity of the EcoC3 cells are 
summarized in Table II. 
It  is  apparent  that  immunization with sub370-12E1AB  and  sub370-12EIA 
viruses induces a  strong syngraft immunity against EcoC3 cells.  With the cell 
doses  used,  no animal  immunized with  these  viruses  developed tumors after 
subcutaneous inoculation challenge. 
In animals immunized with the sub 370-12E 1B virus, the frequency of animals 
developing tumors (Table  II) and kinetics of tumor growth (Fig.  2)  were  not 
different from those in control rats. 
This result indicates that the TSTA  immunity induced by adenovirus  12  is SAWADA  ET  AL.  567 
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FIGURE 3.  The EeoC3 tumors do not grow in animals immunized with viruses carrying the 
E1A transcription unit of Adl2. The  L1S rats were injected twice with  1.5  ×  10  s  PFU of 
recombinant viruses (0.5 ml). The control rats received two 0.5-ml injections of the lysate of 
noninfected 293 cells.  3 wk after the second injection the rats were challenged with various 
doses of the EeoC3 cells: A, 2.5 ×  106; B, 5 X 10s; C,  107; D, 2 ×  107. The growth of tumors 
was monitored in each group of not less than three animals: 0, control animals; O, sub370- 
12E1A; A, sub370-12E1AB. 
TABLE  II 
Induction of Transplantation Immunity Against Ad l 2-transformed 
Cells in Four Experiments  With A d 5 / A d l 2 Recombinant  Viruses 
Exp. I  Exp. II  Exp. II1  Exp. IV 
Immunization  2 ×  10  6  2 x  10  6  10  7 cells  2 ×  10 7 
cells  cells  cells 
None  8/8  ND*  ND*  ND* 
Control  6/6  5/5  3/3  3/3 
Sub370-12El AB  0/5  0/5  0/5  0/5 
Sub370-12E 1A  0/5  0/5  0/5  0/5 
Sub370-12E 1B  6/6  5/5  ND*  ND* 
8-wk-old LIS rats were injected with ~1.3  x  l0  s PFU of recombinant 
adenoviruses and boosted 1 wk later. Control animals received two doses 
of lysate of the noninfected 293 cells.  3 wk after the second injection, 
the rats were challenged with indicated doses of the EeoC3 cells. The in 
vitro cell passage of the EeoC3 cells was as follows: Exp. I, passage 18; 
Exp.  II, passage 21;  Exp.  Ill, passage 28;  Exp.  IV, passage 23.  The 
individual animals were followed for tumor development for 100 d. 
* ND, not done. 
dependent  on  the  E1A  region.  Immunization  with  virions containing  and  ex- 
pressing  the  E1  early  region  (sub370-12E1AB)  or only the  E1A  Adl2  genes 
(sub370-12E1A) induces a  strong protective immunity.  The  Adl2  E1B genes, 
however, induce no significant protection. Tumor induction was unaffected by 
immunization with sub 370-12E 1B virus. 
Effects of Immunization  With Recombinant Ad5/Ad12 Aden•viruses  on  Tumori- 
genicity of Ad2/T13 Cells.  The conclusions drawn from the effects of immuni- 568  ADENOVIRUS  TUMOR-SPECIFIC  TRANSPLANTATION  ANTIGEN 
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FI~URE 4.  Growth  of Ad2/T13  tumors  in  syngeneic rats  immunized with  recombinant 
adenoviruses. The 8-wk-old rats received two subcutaneous injections (1  wk apart) of 1.3  x 
10 ~ PFU of the recombinant adenoviruses in 0.5 m]. The control rats were injected with 0.5 
ml  lysate extracts of uninfected 293  cells.  3  wk  after the second injection the  rats  were 
inoculated subcutaneously with 4  x  106  Ad2/T13  cells (passage 3)  and were followed for 
tumor development. Mean tumor size in not less than three animals per group is shown: &, 
control rats; 0,  rats immunized with the sub370-12E1A  virus; ×,  rats immunized with the 
sub 370-12E 1AB virus; O, rats immunized with the sub 370-12El B virus. 
zation with recombinant viruses on growth of the EcoC3 tumors could be further 
verified and expanded by a  reciprocal experiment. If the conclusion that ade- 
novirus TSTA activity is a function of the EIA genes is correct, immunization 
with sub 370-12E 1AB and sub370-12EA virions should have no effect on growth 
of Ad2/T13  tumors.  On  the  other  hand,  immunization with  sub370-12E1B 
should  confer  syngraft immunity against  cells  transformed  with  a  group  C 
adenovirus. 
The effects of immunization on growth of the Ad2/T13 tumors are shown in 
Fig.  4.  It is apparent  that tumor growth in animals immunized with sub370- 
12E1AB and sub370-12E1A  viruses, respectively, is not different from that in 
rats immunized with the control 293 ]ysates.  No tumors developed, however, in 
animals immunized with two doses of the sub370-12E1B  virus. Results of three 
independent experiments using challenge with different cell dose are summarized 
in Table III. No protective immunity was seen in animals injected with virions 
containing the E1  region or the E1A subregion, respectively, of Adl2. On the 
other hand, no tumors developed in rats immunized with a  recombinant virus 
sub370-12E1B  containing and expressing the E1A region of Ad5.  This result 
indicates that the Ad5 E1A genes and not the Ad5 E1B genes are responsible 
for induction of adenovirus group C TSTA. 
Discussion 
It has been shown previously that adenoviruses can be subdivided into at least 
two groups according to their TSTA (18). It was demonstrated that immunization 
with Ad2 induced no protection against Adl 2 tumors (4); later it was shown that 
the Adl 2 (strain Huie) induces no immunity against group C adenovirus tumors 
(5). Analysis of TSTA induction by a series of Ad5 mutants in that study strongly SAWADA  ET  AL.  569 
TABLE III 
Induction  of Transplantation  Immunity Against 
Adenovirus 2-transformed  Cells in Three Experiments With 
Ad5/Ad l 2 Recombinant Viruses 
Exp. 1  Exp. II  Exp. Ill 
Immunization  2 X l0  s cells  3 ×  l0  s cells  107 cells 
None  3/3  ND*  ND* 
Control  3/4  3/3  3/3 
Sub370-12E1AB  3/4  3/3  3/3 
Sub370-12E1A  ND*  3/3  3/3 
Sub370-12E I B  0/4  0/3  0/3 
8-wk-old LIS rats were injected with ~1.3 x  108 PFU of  the recombinant 
adenoviruses and boosted with the same dose 1 wk later. Control animals 
received two injections of lysate extracts of noninfected 293 cells.  3 wk 
after the second injection, the rats were inoculated with the indicated 
number of the Ad2/T13  cells.  In  vitro cell passage of the Ad2/T13 
tumor cells in Exp. 1 was 7; in Exp. II and Exp. III, the cell passage was 
3. 
* ND, not done. 
suggested that the adenoviral  TSTA is a  function of the early region  1.  It was 
not possible to determine, however, ifa product of either E1A or E1B or of both 
regions is involved (5). 
An ideal  tool to clarify this  point became available with  the construction  of 
viable recombinant  Ad5/Adl2  viruses. 2 In the three viruses used in this  study 
the early region  1 genes of Ad5 were substituted by the corresponding genes of 
Ad 12 (Fig.  1). It has been demonstrated in earlier studies that these substituted 
regions are indeed expressed in the infected  2 and transformed cells (19). 
In  this  study  we  first  confirmed  the  TSTA  activity of the  Ad5  and  Adl2 
viruses. We also showed that a strong TSTA immunity can be produced against 
tumorigenic cells transformed with a cloned DNA fragment containing only the 
early region El.  These results provide compelling evidence that the adenoviral 
TSTA is a function of the E 1A early region. This evidence is based on the effects 
of immunization on tumor induction with syngeneic Adl 2- and Ad2-transformed 
tumorigenic  cells.  Viruses containing  the  E1A genes of Adl2  induce a  strong 
TSTA  immunity  against  EcoC3  cells expressing  the  E1  region  of Adl2.  The. 
protective effects are not significantly affected by the origin of the E1B region 
in  the  virus  used  for  immunization,  whether  from  Adl2  or  from  Ad5.  The 
sub 370-12E1 B virus containing only the E1B region of Adl 2 has no protective 
effects on the growth of EcoC3 tumors.  The virus containing  Ad5 E1A genes, 
however, induces strong protection against tumors induced by Ad2/T13  cells. 
Tumorigenicity of Ad2/T 13 cells was not affected by either the sub 370-12E 1AB 
or by the sub 370-12E 1  A viruses. 
In  the earlier  studies of effects of immunization  with cells transformed  with 
isolated  fragments  of Adl2  DNA,  the  Acc  I-H  fragment  (0-4.7  map  units) 
transformants failed to induce tumor immunity seen with cells transformed with 
the Hind III-G fragment (0-6.8 map units). The TSTA function was tentatively 
assigned to the left end of the E 1  B region (10). Analysis of a library of syngeneic 
cells transformed in vitro with the cloned fragments of the transforming region 570  ADENOVIRUS  TUMOR-SPECIFIC TRANSPLANTATION ANTIGEN 
revealed that cells transformed with Eco RI-C fragment (0-16.5 map units), Sal 
I-C fragment (0-10.3  map units), and Hind III-G fragment (0-6.8  map units) 
elicit cytolytic responses (11). Cells transformed with the cloned Acc I-H fragment 
(0-4.7  map  units),  however,  failed  to  elicit  cytolytic response  and  were not 
effectively lysed by CTLs or antibody raised against cells expressing both E1A 
and  E1B  regions.  These results suggested  that  the Adl2-specific cell  surface 
antigen  is  also a  product  of the  left end of the  E1B  early region (11).  This 
interpretation  was  supported  by  the demonstration that  the  163  amino acid 
protein  coded by  this  region  is  membrane associated and  can  be  labeled  by 
radioiodination  of the  cell  surface (20).  An  analogous  polypeptide  coded by 
group C adenoviruses has also been localized in part within the plasma membrane 
(21).  By definition, however, tumor-specific transplantation immunity can only 
be assessed in vivo. Data presented here indicate that the E1A rather than the 
E1B  transcription  unit  controls adenoviral TSTA activity. The results of the 
transplantation immunity with both  EcoC3 and Ad2/T13  cells are statistically 
highly significant. The Fisher's exact test analysis shows that the results with the 
EcoC3 cells and sub 370-12E1A and sub370-12El AB viruses are significant at a 
P value of 6.29 x  10 -xl. Experiments with Ad2/T 13 cells and the sub 370-12E 1B 
virus are significant at the level of P  -- 5.95  x  10 -5. The TSTA may be coded 
by the E1A early region; no evidence has been provided as yet, however, that 
the E1A polypeptides are a part of cellular membrane. Alternatively, different 
antigens of cellular origin may be induced by the E 1A genes of Ad5 as compared 
with Adl2. 
The E1A region of different adenovirus serotypes has been shown to  have 
multiple functions relating to tumorigenicity. It was shown to complement the 
ras genes for transformation (22), to selectively modulate expression of the class 
I MHC antigen in the transformed cells (23), to affect the cytoskeleton organi- 
zation in infected cells (24), and to control sensitivity of the transformed cells to 
natural killer cells (19).  Results presented here associate adenovirus E1A genes 
with an additional function: adenovirus tumor-specific transplantation antigen. 
Summary 
Viable recombinant adenoviruses that carry a portion of the type 12 E1A and 
E1B  transcription  units  in  a  type  5  background  were used  to  identify genes 
controlling expression of the adenovirus tumor-specific transplantation antigen 
(TSTA). The TSTA immunity is not crossreacting between the group A  and 
group C adenovirus serotypes. Viruses carrying the E 1A region (sub  370-12E 1A), 
or  both  E1A  and  E1B  (sub370-12E1AB)  regions  of Adl2,  induce a  strong 
transplantation immunity against tumors induced by syngeneic cells transformed 
with adenovirus  12,  but  fail  to  induce any protection against  syngeneic cells 
transformed with adenovirus 2.  Immunization with the virus carrying only the 
E1B region (sub370-12E1 B) of adenovirus 12 induces no immunity to adenovirus 
12 transformed cell line, but confers a strong protection against cells transformed 
with adenovirus 2.  These results provide strong evidence that the adenovirus 
tumor-specific transplantation antigen is a function of the E1A early region. 
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